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tematic literature review was conducted to identify articles published in English 
language journals that evaluated the rate of adherence to medications in patients 
with chronic disease. Relevant studies were identified using PubMed, EMBASE, and 
the Cochrane Library databases with a search window from January 2002 through 
August 2013. Twenty-two observational studies reporting adherence were identified 
by two independent reviewers. Of these publications, 7 reported complete informa-
tion on relevant endpoints of studies in patients with osteoporosis. Meta-analyses 
examined 1) mean difference (MD) in adherence (defined using average medica-
tion possession ratio [MPR]) between QW and QD dosing groups and 2) odds ratio 
for adherence (defined using a cut-off of MPR ≥ 80%) for QW versus QD dosing. 
Heterogeneity was assessed using I42 values and meta-analyses utilized both fixed 
and random effects models. Results: The random effects meta-analysis revealed a 
significantly greater MPR with QW compared to QD dosing (pooled MD= 12.29% [95% 
confidence interval (CI) 10.76%-13.82%]; n= 9 [data reported in 7 publications]). Due 
to the high level of heterogeneity (I2= 83.4%), the fixed effects model results are not 
appropriate to report for the pooled MD. When examining the odds ratio for adher-
ence, both fixed and random effects models provided similar results due to the low 
level of heterogeneity (I2= 7.9%; n= 5 [data reported in 3 publications]). Using either 
model, the pooled odds of being adherent (MPR ≥ 80%) in the QW dosing group was 
approximately 1.9 times the odds in the QD dosing group (random effects OR= 1.90 
[95% CI 1.81-2.00]; fixed effects OR= 1.92 [95% CI 1.84-1.99]). ConClusions: In our 
meta-analysis, QW dosing was associated with higher MPR values and greater odds 
of adherence compared to QD dosing in patients with osteoporosis.
Risk ManageMent studies
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Labreche M, Johnson ES
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objeCtives: Increasing morbidity related to Clostridium difficile infection (CDI) moti-
vates methods to identify patients for preventive measures. We developed a risk 
score that can be calculated automatically upon hospital admission based on an 
electronic health record and used by inpatient pharmacists to identify patients who 
would benefit from antibiotic review and patient education. Methods: We assem-
bled a cohort of Kaiser Permanente Northwest patients with a hospital admission 
between 2005 and 2012 and identified CDIs in the six months following admission, 
inclusive of the initial hospitalization. Using Cox regression, we synthesized a priori 
predictors into a risk score, in which a higher number of points indicated higher risk 
for CDIs. We plotted the observed six-month CDI risk for each decile of predicted 
risk. Results: We identified 721 CDIs in the six months following 54,186 hospital 
admissions, an incidence of 13.8 CDIs per 1000 patients. Patients with the highest 
predicted CDI risk had an observed incidence of 53 CDIs per 1000 patients--more 
than 25 times higher than the lowest-risk decile. Pre-admission patient charac-
teristics that doubled the risk of CDI, were age 40 years or greater; use of high-risk 
antibiotics; chronic kidney disease requiring dialysis; liver disease; and more than 
7 days of hospitalization within 60 days. The score differentiated patients who 
develop CDI, an extended C-statistic of 0.75. Predicted risk for CDI agreed closely 
with observed risk. ConClusions: Our risk score accurately predicted risk for CDI 
using pre-admission characteristics. Accurate predictions among the highest-risk 
subgroup of patients allow for the identification of patients who could be targeted 
for and who would likely benefit from pharmacist review of inpatient antibiotic 
use or educational efforts at the time of discharge planning, an improvement over 
simpler stratification strategies (e.g., class of antibiotic).
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objeCtives: To determine the association between warfarin discontinuation and 
stroke risk among patients with non-valvular atrial fibrillation (NVAF). Methods: 
This is a historical cohort study of adult patients (≥ 18 years of age) with NVAF 
who were on warfarin in the MarketScan Commercial and Medicare Supplemental 
Claims and Encounters Database (01/2008-06/2012). Warfarin discontinuation was 
defined as a gap of ≥ 45 days in warfarin prescription within 1 year after initiation. 
Patients with and without warfarin discontinuation were matched at a 1:1 ratio 
using a propensity score method. Matched patients were followed for up to one year 
to determine risks of ischemic stroke, transient ischemic attack (TIA), and hemor-
rhagic stroke. Patient follow-up started from the discontinuation dates for discontin-
ued patients and after the same duration of warfarin therapy for matched persistent 
patients. A multivariate Cox proportional hazards model was used to determine the 
association between warfarin discontinuation and stroke risk after adjusting for 
patient baseline demographic/clinical characteristics. Results: A total of 27,000 
discontinued and persistent patients were included in the final analysis. According 
to the descriptive analysis, discontinued patients had higher rates of ischemic stroke 
than persistent patients (0.99 vs. 0.52 per 100 patient years, P< 0.001), while the rates 
of TIA (1.15 vs. 0.93 per 100 patient years, respectively; P= 0.13) and hemorrhagic 
stroke (0.25 vs. 0.19 per 100 patient years, P= 0.31) were similar between the two 
groups. After adjusting for patient characteristics, warfarin discontinuation was 
associated with significantly increased risk of ischemic stroke (hazard ratio [HR]: 
2.04; 95% confidence interval [CI]: 1.47-2.84) and TIA (HR: 1.36; 95% CI: 1.04-1.78) 
pared health outcomes (quality of life, productivity, resource use) across adherent 
vs. non-adherent respondents. Results: 369 respondents with valid adherence 
data were included in the analyses. Mean age was 62.5 years (SD= 10.5) and most 
respondents were insured (97.6%), nonsmokers (85.9%), and unemployed or disabled 
(65.0%). 23.3% were non-adherent at z-scores> 0 (corresponding to MMAS-4> 0 and 
MMAS-8> 1), and this did not differ significantly across the treatment groups. Across 
treatments, non-adherent vs. adherent behavior was associated with significantly 
poorer health utilities (0.684 vs. 0.734, respectively), worse mental health status 
(46.0 vs. 51.9), greater impairment while working (24.2% vs. 10.5%) and overall work 
impairment (24.9% vs. 13.7%), all p< .05. Non-adherence was associated with non-
significantly higher likelihood of hospitalization in the prior 6 months (24.4% vs. 
18.0%, p= .19). ConClusions: Self-reported non-adherence to oral ET in women 
with BC was common and associated with statistically significant decrements in 
health-related quality of life, as well as work productivity impairments. Given the 
increasing use of oral ET in BC and detrimental effects of non-adherence, interven-
tions to improve adherence in those at highest risk should be developed and tested.
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objeCtives: Current practice guidelines recommend antiplatelet therapy (AT) for 
ACS patients during and after hospital discharge. Nonadherence has been associ-
ated with higher risks of thrombosis, MI and mortality. Real-world studies of AT 
adherence post-discharge have been limited by lack of access to inpatient prescrip-
tions. This study examines ACS mortality, hospital readmission, and health care 
costs by AT adherence post-discharge. Methods: Patients hospitalized for ACS 
between 7/2009-7/2012 were identified from IMS Acute Coronary Syndrome Disease 
Records, which link patient-level information from IMS PharMetrics PlusTM health 
care claims data, IMS hospital charge data master, IMS ambulatory electronic medi-
cal record and mortality data derived from the Social Security Death Index. Patients 
with no diagnosis of ACS 180 days before hospital admission, and with confirmed 
inpatient AT therapy, were followed until the earlier of 360 days post-discharge or 
date of death. Adherence was measured by receipt of AT within 30 days post-dis-
charge and by proportion of days covered (PDC) for the 360 day period post-discharge 
or up to the dates of death and readmission. Adjusted estimates controlled for 
patient demographics and CV risk measured pre-index, using logistic regression, 
Cox regression, and GLM. Results: Of 2,994 patients selected for analysis, the 1,497 
(49%) filling a script for AT within 30 days post-discharge had lower mortality (1.6% 
vs. 6.4%, p< 0.0001), readmission rates at 30 days (7.8% vs. 14.6%, p< 0.0001), and costs 
($24,772 vs. $31,691, p= 0.001) compared to patients not filling. After adjusting for 
patient characteristics, higher compliance (PDC) post-discharge was associated with 
reduced risks of mortality (HR= 0.238, 95% CI: 0.158-0.359), readmission (HR= 0.423, 
95% CI: 0.364-0.512), and lower costs (p= 0.004). ConClusions: Nonadherence with 
AT immediately after discharge and within 360 days was associated with higher 
mortality, readmissions, and costs. Study results show a significant opportunity to 
improve patient outcomes and reduce costs through higher AT adherence.
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objeCtives: To describe the adherence and patient reported outcomes (PROs) of 
rheumatoid arthritis (RA) patients taking biologic drugs enrolled in a specialty phar-
macy (SP) program. Methods: A retrospective analysis of pharmacy claims and 
PRO data for RA patients enrolled in a SP program and receiving biologic drugs from 
12/1/2011 through 10/31/2013 was conducted. Patients with a primary diagnosis of 
RA (ICD-9 CM: 714.xx) were included. Only those with at least two pharmacy claims 
and those with a baseline and at least one follow-up of PRO measures were analyzed. 
Patients who were < 18 or ≥ 90 years of age, who switched drugs or who declined 
involvement were excluded. Medication possession ratio (MPR) was used as a proxy 
for adherence and calculated based on pharmacy claims data. PROs were collected 
via telephone and included pain and fatigue measured on a numeric rating scale 
(NRS, scale: 0-10), and functional status measured using the Health Assessment 
Questionnaire-II (HAQ-II, scale: 0-3). Outcomes were collected at baseline and 
approximately every six months for the duration of the patients’ enrollment. 
Descriptive statistics, Wilcoxon signed-rank, and correlations were used to analyze 
the data. Results: A total of 2,385 patients were included. The mean age of patients 
was 54.80 years (±12.88) and 70.48% were female. The average MPR for all patients 
was 86.47% (±15.14%) over an average of 403.89 days (±167.20). Overall, 36.27% and 
38.87% of patients had at least 1-point decrease on the pain NRS and fatigue NRS, 
respectively. Any reduction in the HAQ-II score was observed in 46.79% of patients at 
follow-up, which was statistically significant (-0.065, p< 0.001). ConClusions: RA 
patients receiving biologic medications enrolled in a SP program had high therapy 
adherence and realized decreases in pain, fatigue and improvement in functional 
status from baseline.
Ma4
systeMatic liteRatuRe Review and Meta-analysis of Medication 
adheRence with once weekly veRsus once daily theRaPy in Patients 
with osteoPoRosis
Iglay K, Joshi K, Cao X, Mavros P, Tunceli K
Merck Sharp & Dohme Corp., Whitehouse Station, NJ, USA
objeCtives: To compare medication adherence rates for once weekly (QW) versus 
once daily (QD) dosing regimens in patients with osteoporosis. Methods: A sys-
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were analyzed by means of descriptive statistics and linear regression mode-
ling. Results: Most diabetes patients are reporting pain, only 29% of the patients 
reports no pain or discomfort. 48% of the patients report mobility problems, 36% 
reports problems with usual activities, 34% report problems with anxiety or depres-
sion. Only 10% of diabetes patients report problems with self-care. From a regression 
modeling point of view, with EQ-5D dimensions used to predict VAS scores, pain/
discomfort scores have a standardized β –value of -0,44. For the other dimensions 
the following β –values were found anxiety/depression (-0,3), mobility (-0,22), self-
care (-0,21), and usual activities (-0,09). ConClusions: From the five dimensions 
included in the EQ-5D-5L pain/discomfort has the largest negative influence on 
the HRQoL of diabetes patients, problems with usual activities and self-care have 
least impact. Although a lot of research has already been conducted in the field of 
diabetes patient pain/discomfort management further investigation is warranted.
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objeCtives: Current treatments for chronic hepatitis C (CHC) are frequently asso-
ciated with complex regimens and serious adverse events. Little is known about 
the impact of these treatment attributes on health state utilities. The purpose of 
this study was to estimate the utility or disutility (i.e., utility decrease) associated 
with treatment administration and adverse events of CHC treatments. Methods: 
Health states were drafted based on literature review and expert clinician inter-
views. General population participants in the UK (London, Edinburgh) valued the 
health states in time trade-off (TTO) interviews with both 10-year and 1-year time 
horizons. The 14 health states described hepatitis C with variations in treatment 
attributes: number of tablets per day, weekly injection, fatty food requirement, and 
six adverse events. Results: A total of 182 participants completed interviews (50% 
female; mean age = 39.3y). In treatment regimens without injections, greater num-
bers of tablets were associated with slightly lower utility (1 tablet = 0.80; 2 tablets = 
0.80; 3 tablets = 0.80; 7 tablets = 0.79). Utilities for health states describing regimens 
with oral and injectable medication were 0.77 (7 tablets), 0.75 (12 tablets), and 0.71 
(18 tablets). Addition of a weekly injection to a 7-tablet regimen had a disutility 
of -0.02. The requirement to take tablets with fatty food had a disutility of -0.04. 
Adverse events were associated with substantial disutilities: mild anemia, -0.12; 
severe anemia, -0.32; flu-like symptoms, -0.21; mild rash, -0.13; severe rash, -0.48; 
depression, -0.47. These utilities are from the 10-year TTO; one-year scores were very 
similar. ConClusions: Adverse events and greater treatment regimen complexity 
were associated with utility reductions, suggesting a perceived decrease in quality 
of life beyond the impact of hepatitis C itself. The resulting utilities may be used in 
models estimating and comparing the value of treatments for hepatitis C.
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assessing factoRs associated with self-RePoRted health status in 
the united states using a stRuctuRal equation Model
Zhao Y, Gu NY
University of New Mexico, Albuquerque, NM, USA
objeCtives: To assess the relationship between self-reported health status and 
lifestyle, access to health care and individual characteristics using a U.S. representa-
tive sample. Methods: A cross-sectional study using the 2011 US Behavioral Risk 
Factor Surveillance System (BRFSS) Survey database was performed. A structural 
equation model (SEM) was applied to investigate individual characteristics factors 
(age, body mass index (BMI), income and education levels), lifestyle factors (fruit, 
vegetable and alcohol consumptions and exercise levels), and access to health care 
factors (statuses on insurance, private health care provider and barrier to health 
service due to cost) that influence various self-reported health statuses (general 
health status, physical health status and mental health status). Results: The mean 
age of the study population was about 43.5 years with 51.2% being female. The 
measures of model fitness (RMSEA< 0.05 is 0.951; GFI= 0.954) showed the internal 
structure of the model was acceptable and the observed variables would suffice in 
accounting for latent variables. The proportion of variance in each indicator was 
explained well by its respective latent variable (e.g. 58.7% of variance in general 
health, 60.4% in insurance and 59.0% in income were explained). All independent 
latent variables (access to health care, individual characteristics and lifestyle) were 
significantly associated with health status. Individual characteristics factors have 
the largest effect (β = 0.719) on health status, followed by lifestyle factors (β = 0.141) 
and access to health care factors (β = 0.136). ConClusions: Our findings show that 
improved access to health care and lifestyle were associated with increased self-
reported health status. In particular, older individuals with high BMI index and low 
socioeconomic status were more likely to report worse health status.
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develoPMent and validation of an aPPRoach to inteRPRet 
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objeCtives: There is great interest in using computerized adaptive tests (CAT) to 
assess health outcomes. CATs are based on Item Response Theory (IRT) and yield 
a numeric estimate, but it is difficult to interpret the health status and clinical 
meaning from these scores. Item maps generated from IRT analyses and book-
marking procedures facilitate development of levels, and provide a meaningful 
context for CAT scores. We aim to develop and validate the levels for Spinal Cord 
Injury Functional Index (SCI-FI) used as a functional outcome measure for persons 
with SCI. The specific objectives are: (i) Develop levels for five SCI-FI domains: 
basic mobility, self-care, fine motor, wheelchair and ambulation; (ii) Determine 
but not significantly increased risk of hemorrhagic stroke (HR: 1.43; 95% CI: 0.80-
2.56). ConClusions: Warfarin discontinuation is associated with increased risk of 
ischemic stroke and TIA in NVAF patinets. Further study is warranted to examine 
long-term clinical and economic outcomes of warfarin discontinuation.
Ri3
disPaRity in high Risk Medication use between dual and non-
dual eligible MedicaRe advantage beneficiaRies: a decoMPosition 
analysis
Pulungan Z, Parente A, Mehta S, Jones B, Teigland C
Inovalon Inc., Bowie, MD, USA
objeCtives: The CMS Five Star Rating system for Medicare Advantage (MA) informs 
beneficiaries about plan performance and determines Quality Bonus Payments. High 
Risk Medication (HRM) use is a triple weighted measure defined as the percent of 
beneficiaries aged 65+ who received two or more fills for a drug with high risk of 
serious side effects in the elderly. This analysis evaluates differences in HRM use 
between dual eligible (DE) and non-DE members and examines the contribution of 
socio-demographic and clinical characteristics to observed disparities. Methods: 
The study used a nationally representative administrative claims database of 1.5 
million MA members in 2011-2012 (measured in member years): 232,273 DE (female: 
66.3%; average age 75.4) and 1,251,145 non-DE (female 57.4%; average age 75.2). 
The Linear Probability Model (LPM) and Blinder-Oaxaca decomposition techniques 
with Neumark weighting formula were performed. Results: HRM rate was 32.2% 
higher in DEs (16.8% vs. 12.7%). The decomposition analysis found member char-
acteristics accounted for only 48% of the performance gap (“explained gap”); 52% 
was attributed to differential effects of member characteristics on HRM use (“unex-
plained gap”). The Charlson Severity Score indicates more complex comorbidities 
in DEs (2.34 vs. 1.77) and explained 70.6% of the difference in HRM use; disability as 
original reason for entitlement explained 23.3%. Members of a Preferred Provider 
Organization (PPO) and older members were less likely to use HRMs, while females 
and low income members were associated with higher use. ConClusions: This 
study provides information about the contribution of socio-demographic and clini-
cal characteristics to higher use of HRMs in DEs, and can support targeted interven-
tions to reduce the performance gap. The analysis further demonstrates that more 
than half the disparity is not explained by the member characteristics evaluated 
and points to the need for further research to understand the factors behind the 
unexplained DE gap.
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staPhylococcus auReus (MRsa) bacteReMia in the united states
Pawar AM, Willey CJ, Caffrey AR
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objeCtives: MRSA bacteremia is associated with significantly greater mortal-
ity, length of stay (LOS), and hospital costs compared to methicillin-susceptible S. 
aureus (MSSA) bacteremia. With the changing epidemiology of S. aureus infections, 
we sought to identify risk factors for MRSA bacteremia. Methods: Our case-control 
study identified MRSA (cases) or MSSA (controls) bacteremia hospitalizations, using 
diagnosis codes, from the 2009 Nationwide Inpatient Sample (n= 7,810,762). These 
were further categorized into community-associated (principal diagnoses) or hospi-
tal-associated (secondary diagnoses) infections. Significant independent predictors 
of MRSA bacteremia, as compared to MSSA bacteremia, were identified from logistic 
regression models. Differences in outcomes were assessed with χ 2 or Wilcoxon 
tests. Results: Our study included 12,907 MRSA and 9,380 with MSSA bactere-
mia hospitalizations. Lower median household income (< $38,999 versus $63,000 
or more) was significantly associated with MRSA bacteremia (odds ratio [OR]= 1.34, 
p< 0.01). African Americans (OR= 1.32, p< 0.01) were at higher risk while Asian or 
Pacific Islanders (OR= 0.80, p= 0.02) were at lower risk of developing MRSA bacte-
remia compared to Whites. The presence of certain comorbidities increased the 
risk of MRSA bacteremia as compared to MSSA (p< 0.01): paralysis (OR= 1.65), other 
neurological disorders (OR= 1.38), chronic pulmonary disease (OR= 1.27), peripheral 
vascular disease (OR= 1.27), psychosis (OR= 1.23), weight loss (OR= 1.19), and renal 
failure (OR= 1.13). Alternatively, the odds of other comorbidities were lower with 
MRSA bacteremia (p< 0.01): coagulopathy (OR= 0.85), hypertension (OR= 0.84), and 
metastatic cancer (OR= 0.77). Similar results were found in community-associated 
and nosocomial infection subgroups. MRSA was associated with significantly higher 
mortality (MRSA 63%, MSSA 37%), LOS (MRSA 16 days, MSSA 14 days), and hospital 
costs (MRSA $114,176, MSSA $104,408) (p< 0.01). ConClusions: Our study identified 
additional predictors of MRSA bacteremia among a large, nationally representative 
source population of 7 million patients. These included income, race, and comorbidi-
ties, which were either risk factors for MRSA bacteremia, as compared to MSSA, or 
protective against MRSA, indicating a greater association with MSSA.
utility MeasuReMent studies
ut1
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objeCtives: EQ-5D is a frequently applied instrument to measure Health Related 
Quality of Life (HRQoL) among patients. The HRQoL is measured based on a 
5-item questionnaire covering: mobility, self-care, usual activities, pain/discom-
fort, and anxiety/depression. The objective of our study was to identify which of 
these 5 dimensions has the biggest influence on the HRQoL scores of diabetes 
patients. Methods: A cross-sectional survey of diabetes patients (n = 1480) liv-
ing in the United States. Each patient completed a questionnaire, which included 
the EQ-5D-5L instrument and accompanying VAS. Scores provided by the patients 
